Key result
Eosinophilic myocarditis diagnosis relies on endomyocardial biopsy and CMR, while early glucocorticoid and anticoagulant therapy may prevent intermediate disease stage development.
This review highlights the importance of endomyocardial biopsy and CMR for diagnosing eosinophilic myocarditis, and the role of early glucocorticoid and anticoagulant therapy in preventing disease progression.
Answers are grounded in this paper and cite their sources.
Gene associations in eosinophilic myocarditis are hypothesis-generating; larger studies needed before clinical translation.
Eosinophilic myocarditis is a type of inflammatory cardiomyopathy characterized by eosinophilic infiltration into myocardial tissue. The accurate myocarditis incidence rate is difficult to determine because of the clinical limitations of an endomyocardial biopsy. The primary pathogenesis of eosinophilic myocarditis is the release of related substances by eosinophils, leading to cell membrane damage and cell destruction. However, evidence suggests that specific genes play a role in myocarditis development.As CMR imaging availability increases, the diagnosis rate of eosinophilic myocarditis will increase. The diagnosis of myocarditis mainly depends on an endocardial biopsy. Glucocorticoids can relieve patients' symptoms, but the early use of steroids may prevent intermediate disease stage development (i.e., thrombonecrosis and fibrosis with wall thrombosis). Anticoagulant therapy may also affect disease development. In addition to routine follow-up, a regular myocardial biopsy should be considered for discharged patients, if possible.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2021) conducted a review in Eosinophilic myocarditis. Eosinophilic myocarditis diagnosis relies on endomyocardial biopsy and CMR, while early glucocorticoid and anticoagulant therapy may prevent intermediate disease stage development.
Synapse has enriched 10 related papers. Consider them for comparative context: